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Aim. The contemporary incidence of heart failure (HF) in patients with chronic coronary 
syndrome is unclear. We aimed to study the incidence and predictors of cardiovascular (CV) 
death, HF hospitalization or new-onset HF not requiring hospitalization, in patients included 
in the CLARIFY registry. 
Methods and results. CLARIFY is a contemporary, international registry of ambulatory 
patients with chronic CAD, conducted in 45 countries. At baseline, data on demographics, 
ethnicity, CV risk factors, medical history, cardiac parameters and medication were collected. 
Patients were followed-up yearly up to 5 years. In this analysis we included 26769 patients 
with no HF history. At 5-year follow-up, 4393 patients (16.4%) reached the primary endpoint 
comprising CV death, HF hospitalization or new-onset HF.  Only 16.7% of them (N = 732) 
required hospitalization for HF. All-cause death occurred in 6.6% of patients (61.4% were 
cardiovascular). Age over 70 years, left ventricular ejection fraction <50%, CCS class >2 
angina, atrial fibrillation or paced rhythm on the ECG, body mass index <20, and a history of 
stroke, were the most robust predictors of the primary outcome.  Age <50 years, Asian 
ethnicity, and percutaneous revascularization were negative predictors of the outcome. 
Conclusion. A sizeable proportion of patients with chronic coronary syndrome develop HF, 
which only infrequently requires hospitalization. Early identification of patients with HF may 
lead to early treatment, and help to further decrease mortality and morbidity. This concept 
needs confirmation in future studies.  
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Coronary artery disease (CAD) remains the leading cause of death on the global level 
[1]. It is also one of the most important causes of heart failure (HF) [2, 3]. In patients with 
CAD, HF may be not only caused by acute myocardial tissue loss due to myocardial 
infarction (MI), but also by left ventricular remodelling or severe chronic ischaemia. In 
developed countries, 1-2% of the adult population suffer from HF, with much higher 
prevalence in the elderly [2]. Despite constant advances in management, mortality in HF 
remains high, and patients require frequent hospital admissions [4]. In the elderly, 5-year 
mortality after a first MI tends to decrease, while the rate of subsequent HF increases [4]. 
Hospitalization for HF represents a great public health and financial burden. Chronic coronary 
syndromes account for a high proportion of cardiac hospitalizations, with a growing number 
of HF admissions over time [5]. However, a large proportion of patients with newly 
diagnosed or worsening HF may not require hospitalization, either because of less severe 
symptoms, or a growing tendency to provide ambulatory treatment [6]. These patients are 
generally neglected in clinical studies, but their inclusion in the analyses appears to be of 
importance [6-8]. In any case, development of HF puts patients at high risk for mortality [9-
12]. Although the incidence of HF events has been previously studied in patients with stable 
CAD and in those with a history of MI [6,11,13,14],  within the entire spectrum of  chronic 
coronary syndromes, HF outcomes remain relatively poorly explored, which is especially 
relevant in patients who do not require hospital admission [7,8]. In addition, previous data 
come mainly from clinical trials, as opposed to registries which provide data more 
representative of routine clinical practice.  
In major registries involving patients with chronic CAD, between 7 and 28% were 
diagnosed with HF [15]. However, over the last decades, there has been a clear change in the 
characteristics of patients with CAD. Contemporary patients are older and more likely to have 
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a history of MI or coronary revascularization than before. The prevalence of HF, diabetes, 
chronic renal and pulmonary disease, and peripheral artery disease have increased [15].  
Data on the incidence of HF in patients with chronic CAD are limited [10]. Therefore, we 
aimed to study the incidence of HF outcomes and their predictors in a contemporary 
population of patients with  CCS included in the prospeCtive observational LongitudinAl 
RegIstry oF patients with stable coronarY artery disease (CLARIFY), a worldwide registry of 
over 30 000 ambulatory patients. CLARIFY is registered in the ISRCTN Registry of clinical 
trials (IRSCTN43070564).  
Methods 
Study design  
Rationale, design, and baseline characteristics of the entire CLARIFY population have 
been previously published [16,17]. Briefly, 32703 ambulatory patients with chronic CAD 
were enrolled between November 2009 and June 2010 in 45 countries in Europe, Middle East, 
Asia, Africa, and North and South America. Patients had to fulfil at least one of the following 
criteria to be eligible for the study: myocardial infarction or coronary revascularization 
(coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)) >3 
months before enrolment, coronary stenosis >50% on angiography, or angina with 
documented myocardial ischaemia. The main exclusion criteria were: hospitalization for 
cardiovascular (CV) disease within previous 3 months, planned revascularization, and any 
condition that might affect participation or the 5-year follow-up. Study sites were selected by 
national coordinators among cardiologists, internists and general practitioners, based in 
different urban, suburban and rural areas, in order to obtain a sample best representing the 
disease epidemiology. Participating physicians were asked to manage patients according to 
their usual practice. No specific diagnostic or therapeutic procedures were required. Each 
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physician was requested to enrol 10-15 consecutive ambulatory patients. Patients were 
followed-up annually for up to 5 years. 
CLARIFY was conducted according to the principles specified in the Declaration of 
Helsinki. The research protocol was approved by the Ethics Committees and regulatory 
agencies according to national and local legal requirements. All participants gave written 
informed consent before study entry.  
The present study is a post-hoc analysis of data from the CLARIFY registry. Patients 
with a history of hospitalization for heart failure and/or heart failure symptoms at baseline 
were excluded from the analysis.We did not exclude patients based on EF availability or 
value. 
Data collection 
Data were collected using standardized electronic case-report forms available in a 
local language, completed at baseline and at annual visits. In case of missed visits, telephone 
contacts with the patients or their representatives, or site visits by investigators were 
attempted. If no contact was possible, vital status was retrieved from country databases 
whenever legally permitted. All data were centrally verified for accuracy, consistency and 
completeness. To assure data quality, on-site audits of all the data were performed in five 
percent of randomly selected centres over the study period (1% per year). At baseline, data on 
demographic characteristics, ethnicity, risk factors, medical history, cardiac parameters, and 
current medication were collected. At each annual visit clinical outcomes were recorded.  
Clinical outcomes 
For the purpose of the current analysis the primary outcome was defined as a 
composite of CV death, hospitalization for HF or new HF symptoms not requiring hospital 
admission (new-onset HF). The secondary outcome was a composite of CV death or HF 
hospitalization. We also analysed the incidence of all-cause death, the combination of HF 
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hospitalization and new-onset HF, and each component of the primary outcome. If new-onset 
HF and HF hospitalization were recorded on the same day, only the latter was taken into 
account. 
CV death was defined as death within 28 days after MI or stroke, any sudden death 
including unobserved and unexpected death unless proven otherwise by autopsy, death 
ascribed to heart failure, ruptured aneurysm, pulmonary embolism, amputation (except for 
trauma and malignancy), following cardiac or vascular procedure/operation, or any death not 
classified as non-cardiovascular. Hospitalization for HF was diagnosed if caused by presence 
of signs and symptoms of HF. New-onset HF was defined as the presence of new signs and 
symptoms of HF confirmed by non-invasive or hemodynamic measurements, and not 
requiring hospital admission. 
Statistical analysis 
Baseline characteristics are presented for all patients and split by occurrence of the 
primary outcome. Continuous variables are described using mean ± standard deviation and 
compared between groups using t-tests, whilst counts and percentages are used to describe 
categorical variables which were compared between groups using Chi-Square tests for 
association. Kaplan-Meier curves were generated for both the primary and the secondary 
outcomes and are shown as incidence curves.  
For the primary outcome, univariate Cox regression models were fitted using each of 
the baseline characteristics to evaluate their independent association with outcome, with 
hazard ratios and corresponding 95% confidence intervals reported. Multivariable Cox 
regression models were then fitted to further assess the associations. A stepwise procedure 
was used in which all selected baseline covariates were permitted entry into the starting model 
and then sequentially removed, and in turn considered for re-entry, based on the covariate p-
value. A 5% significance level was set and the final model was obtained when no more 
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covariates met the removal or re-entry significance threshold. A multivariable Cox regression 
model was then fitted for the secondary outcome using the same covariates obtained from the 
final stepwise primary outcome model. Forest plots were generated displaying hazard ratios, 
95% confidence intervals and p-values for the covariates from the final stepwise model for the 
primary outcome, and from the corresponding model for the secondary outcome. 
Analysis was conducted in SAS Version 9.4 and R Version 3.3.3. 
All statistical analyses were performed by the independent centre (Robertson Centre 
for Biostatistics, University of Glasgow, Glasgow, UK). 
Results 
Patient characteristics 
In the whole CLARIFY registry population (N = 32703), 5-year follow-up was available in 
32378 (99.0%) patients.  A history of hospitalization for HF or current HF symptoms was 
present at baseline in 5607 (17.3%) patients.  These patients were excluded. Finally, 26769 
patients were included in the current analysis (Figure 1). Patient characteristics at baseline are 
presented in Table 1. Mean patients’ age was 64.2+10.4 years, and 78.4% were male. Their 
ethnicity was differentiated, with around 60% of Caucasian, and 20% of Asian origin. Nearly 
60% of patients were current or former smokers, pproximately 30% had diabetes, around 70% 
had hyperlipidaemia or hypertension, and more than 70% were obese or overweight. Almost 
60% of patients had a history of MI and/or myocardial revascularization, and only a minority 
had CCS class >2 angina or documented chest pain with myocardial ischemia. Blood pressure 
and heart rate were relatively well controlled. Among those with available data (N=19397, 
72.5%), atrial fibrillation was present in 2.6%, and paced rhythm in 1.3% of patients. Left 
ventricular ejection fraction measured by echocardiography (available in N=17654, 65.9%), 
was normal  in 74.7%, mildly depressed (40-50%) in 20.6%, and severely depressed (<40%) 
in 4.7% of patients. Among patients who underwent coronary angiography (N=23721, 88.6%) 
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54% had multivessel coronary disease. The use of guideline recommended medical therapy 
was high. Antiplatelet treatment was prescribed in 95.7%, lipid-lowering drugs in 92.6%, and 
beta-blockers in 73.7% of  registry participants.   
Clinical outcomes 
During follow-up, 4393 patients (16.4%) reached the primary outcome of CV death, 
hospitalization for HF or new HF symptoms not requiring hospital admission. There were 
substantial differences between those with and without the primary outcome (Table 1). 
Kaplan-Meier curves for the primary and secondary outcome are provided in Figure 2. The 
overall clinical outcomes are presented in Table 2. In addition, outcomes by sex and race are 
shown in Supplementary Tables 1 and 2. The combination of CV death and hospitalization for 
HF occurred in 6.4%, all-cause death in 6.6%, and CV death in 4.1% of patients (61.4% of all 
deaths). Among 3022 patients (11.3%) who presented with new-onset HF symptoms, HF 
hospitalization was subsequently necessary in 210, and CV death occurred in 196 (6.9 and 
6.5% of this group, respectively). In 522 subjects (2.0%) HF hospitalization was the initial 
event, counted as a component of primary outcome. In addition, 210 subjects required HF 
hospitalization after the initial HF diagnosis. Eventually, out of the 4393 patients who reached 
the primary outcome 732 (16.7%, or 2.8% of the entire study population) underwent  
hospitalization for HF.  
Factors predicting heart failure outcomes 
Figure 3 shows predictors of the primary outcome. Age over 70 years, left ventricular 
ejection fraction <50%, CCS class >2 angina, atrial fibrillation or paced rhythm on the ECG, 
body mass index <20, and a history of stroke, were the most robust predictors of the primary 
outcome. Female sex, current or former smoking, hypertension, asthma/COPD, diabetes, 
obesity, peripheral artery disease, carotid disease, inadequate heart rate control, systolic blood 
pressure over 140 or under 120 mmHg, multiple vessel disease, previous MI and  coronary 
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arteriography not done were also associated with increased risk of the primary outcome. At 
the same time, age <50 years, Asian ethnicity, and PCI, were associated with reduced risk of 
the outcome. Primary outcome according to the availability and value of baseline EF is shown 
in Supplementary Table 3. 
Since subjects with coronary artery disease are at risk of recurrent coronary events, 
interim acute coronary events were additionally considered. In 154 patients we identified a 
myocardial infarction occurring since baseline up to the year of new HF onset.  Adding this 
information to the previous results from the stepwise model for the primary outcome indicated 
that incident MI was significantly associated with the primary outcome (p<0.0001), in 
addition to MI as recorded from medical history, which also remained statistically 
significantly associated with the primary outcome. 
Predictors of the secondary outcome including CV death and heart failure 
hospitalization are shown in Figure 4. Most predictors were identical, but in comparison to the 
primary outcome, Hispanic ethnicity appeared as a new positive and CABG as a negative 
independent predictor, and the association with sex, obesity, history of hypertension, blood 
pressure and carotid disease was no longer present.  
In addition, predictors of the combined endpoint including new-onset HF and HF 
hospitalization are shown in Supplementary Figure 1. This endpoint is primarily driven by HF 
not requiring hospitalization, and does not include CV death, that might not have been HF-
related.  The determinants did not differ from those for the primary and secondary endpoints. 
Discussion 
Most studies in patients with stable CAD focus on outcomes directly related to 
atherothrombosis, such as CV death, myocardial infarction and stroke [2,8,10,18-21], but the 
presence of HF is recognized as an important prognostic factor [10-12]. However, data on HF 
incidence are generally limited to patients requiring hospitalization [6,11,13,14]. The key 
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novel aspect of the present analysis is the reported onset of HF not requiring hospitalization in 
the setting of real life practice. 
In the present study of ambulatory patients with chronic CAD, free from HF at 
baseline, at 5-year follow up approximately one in six patients (16.4%) achieved the primary 
composite outcome including CV death, hospitalization for HF and new-onset HF. These 
16.4% add to the 17.3% of patients with prior HF (whom we excluded from this analysis), 
indicating that approximately a third of patients with chronic CAD are affected by HF.   
The secondary outcome was the more standard combination of CV death and HF 
hospitalization. It was reached by 6.4% of patients, indicating that most cases of incident HF 
would have been missed if only HF hospitalizations and CV deaths had been taken into 
consideration. Of note, the BIOSTAT-CHF study compared the outcome in inpatients versus 
outpatients with HF. Although inpatients were generally sicker, a substantial proportion of 
outpatients had similar or higher event rates compared to inpatients [84].  
Importantly, while almost 14% of patients developed HF,  only less than one fifth of  
them required hospitalization. Lamblin et al. [11] have recently analysed the incidence of 
hospitalization for heart failure in the CORONOR registry. During the 5-y follow-up 5.7% of 
patients were hospitalized for HF, around twice as many as in our study. This difference may 
reflect a less severe course of heart failure in our patients, the current trend to use out-of-
hospital management strategies, or differences in patient selection. In any case, it indicates 
that the group of patients with new-onset HF with no need for hospitalization should not be 
neglected.  
We identified a number of predictors of the primary outcome. Some, such as older age, 
decreased LVEF, atrial fibrillation, higher body mass index, diabetes, history of hypertension, 
angina, and multivessel CAD, have been previously shown to predict HF hospitalization in 
the CORONOR registry [11]. We previously described the detrimental effect of angina 
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symptoms on the outcome including CV death, MI or stroke in patients with chronic CAD 
[22]. Heart failure outcomes, however, were not analyzed. In agreement with our findings, in 
the REACH registry, patients with angina were at increased risk of HF [23].  
The effect of revascularization on the incidence of HF remains ambiguous. Available 
data on the impact of different modes of coronary revascularization versus optimal medical 
treatment differ between randomized trials and observational data [24]. Contrary to previous 
reports [4,24], we found that previous PCI was associated with decreased HF incidence. 
Interestingly, in the REACH registry, PCI (but not CABG) was linked to a lower risk of CV 
death [25], although this may reflect selection of lower risk patients for PCI.  However, heart 
failure outcomes were not included in their analysis. In addition to the factors that have 
previously been shown to have an impact on development of  HF, we found that female sex, 
systolic blood pressure <120 mmHg, inadequate heart rate control, paced rhythm and any of 
the reversible CV risk factors are predictive of the primary outcome, while Asian ethnicity 
appears to show lower propensity for HF.  
Our population is representative of contemporary patients with CCS and without heart 
failure at baseline, managed in an ambulatory setting in different geographical areas. In the 
present study, the rate of all-cause death at 5 years was lower than in CORONOR [26] and in 
CALIBER [10] studies (6.6% vs 16.2 and 20.6%, respectively). Similarly to our findings, in 
both CORONOR [18,26] and CALIBER [10] a substantial proportion of deaths were non-
cardiovascular. 
It should be noted that the definition of chronic CAD encompasses a wide spectrum of 
patients, and their outcomes are highly dependent on the clinical setting and entry criteria 
(hospitalized vs ambulatory patients, inclusion of patients with heart failure etc.). Trullas et al. 
[27] showed that in the registry setting, even in patients with similar clinical characteristics, 
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HF outcomes may significantly differ. Therefore, in the case of a complex and heterogeneous 
disease such as HF, the results of registries must be interpreted with caution. 
Strengths and limitations of the study 
Strengths. This paper is based on data from the large, contemporary, international 
CLARIFY registry, well reflecting real-world management of ambulatory patients with 
chronic CAD. In the current analysis we used a wide definition of HF, including patients with 
no need for hospitalization, but with the HF diagnosis confirmed by non-invasive or 
hemodynamic assessment. This group of patients is of increasing importance, because they 
represent an early stage of the disease, whose management may prevent future CV events. In 
addition, there is a growing trend to avoid hospitalization of patients with HF, and exclusion 
of this group might significantly distort the image of HF outcomes.  
Limitations.  Our study shares the limitations of observational analyses, with their potential 
intrinsic biases. In CLARIFY, every effort was made to collect accurate data, but only a 
limited number of centres were directly monitored throughout the study. Outcome events 
were investigator reported and did not undergo central adjudication.   We were unable to 
differentiate between HF with reduced versus preserved EF. Since HF events were not 
adjudicated, some cases of HF hospitalization could have been due to acute coronary events. 
Confirmation of HF by non-invasive or haemodynamic measurements was specified in the 
protocol, but there was no requirement for the investigators to describe the imaging tool and 
the findings at the time of HF diagnosis. However, the close similarity between predictors of 
the primary and secondary outcome supports the concept that the diagnosis of new-onset HF 
without hospital admission was generally correct.  
Conclusion 
Data from this contemporary registry of ambulatory patients with chronic CAD 
indicate that during the 5-year follow-up a relatively large proportion of ambulatory patients 
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with chronic CAD and no known HF will develop heart failure, which only infrequently 
requires hospitalization. Patients with left ventricular ejection fraction <50%, CCS class >2 
angina, atrial fibrillation or paced rhythm on the ECG, body mass index <20, and a history of 
stroke, were at the highest risk of reaching the primary outcome). Early identification of 
patients with  HF may lead to early treatment institution, and potentially help to further 
decrease mortality and morbidity in ambulatory patients with chronic CAD. This concept  
needs confirmation in future  studies.  
 
Funding. The CLARIFY registry was supported by unconditional grants by Servier, France. 
 
Disclaimer. The CLARIFY registry enforces a no ghost-writing policy. This manuscript was 
written and edited by the authors, who take full responsibility for the content. 
 
Conflict of Interest 
Dr. Parma reports personal fees from Servier,  outside the submitted work. 
Mr Jasilek has nothing to disclose. 
Ms. Greenlaw reports grants from Servier during the conduct of the study. 
Dr. Ferrari reports grants and personal fees from SERVIER INTERNATIONAL, personal 
fees from MERCK SERONO, grants and personal fees from NOVARTIS, personal fees from 
LUPIN, personal fees from CIPLA, personal fees from PFIZER, personal fees from SPASPA, 
personal fees from DOC GENERICI, personal fees from ALPHA SIGMA, personal fees from 
BAYER, personal fees from BOEHRINGER INGELHEIM,  outside the submitted work. 
Dr. Ford reports grants and personal fees from Servier,  during the conduct of the study; 
personal fees from Servier,  outside the submitted work. 
14 
 
Dr. Fox reports personal fees and non-financial support from Servier,  during the conduct of 
the study; personal fees from AstraZeneca, personal fees from TaurX, non-financial support 
from Armgo, personal fees and non-financial support from Broadview Ventures, personal fees 
from CellAegis,  outside the submitted work;  and Director of Vesalius Trials Ltd. Minimal 
stockholder of Armgo and CellAegis. 
Dr. Tardif reports grants and personal fees from Servier,  during the conduct of the study; 
grants and personal fees from Amarin, grants and personal fees from AstraZeneca, grants, 
personal fees and other from DalCor, grants from Esperion, grants from Ionis, grants and 
personal fees from Pfizer, grants from RegenXbio, grants and personal fees from Sanofi, 
grants and personal fees from Servier,  outside the submitted work;  In addition, Dr. Tardif 
has a patent Pharmacogenomics-guided CETP inhibition issued. 
Dr. Tendera reports personal fees from Servier,  during the conduct of the study; personal fees 
from Bayer, personal fees from Cadila Pharmaceuticals, personal fees from Janssen-Cilag, 
personal fees from Kowa, personal fees from PERFUSE Group, personal fees from Servier, 
personal fees from UCB Pharmaceuticals,  outside the submitted work. 
Dr. Steg reports grants and personal fees from Servier,  during the conduct of the study; grants 
and personal fees from Bayer/Janssen, grants and personal fees from Merck, grants and 
personal fees from Sanofi, grants and personal fees from Amarin, personal fees from Amgen, 
personal fees from Bristol Myers Squibb, personal fees from Boehringer-Ingelheim, personal 
fees from Pfizer, personal fees from Novartis, personal fees from Regeneron, personal fees 
from Lilly, personal fees from AstraZeneca, personal fees from Servier, personal fees from 







1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific 
mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic 
analysis for the Global Burden of Disease Study 2017. Lancet 2018; 397:1736-1788. 
2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, 
Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, 
Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH,  
van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic 
heart failure. Eur Heart J 2016; 37:2129-2200. 
3. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 
2016; 13:368-378. 
4. Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. Declining in-
hospital mortality and increasing heart failure incidence in elderly patients with first 
myocardial infarction. J Am Coll Cardiol 2009; 53:13-20. 
5. Gąsior M, Pres D, Wojakowski W, Buszman P, Kalarus Z, Hawranek M, Gierlotka M, 
Lekston A, Mizia-Stec K, Zembala M, Poloński L, Tendera M. Causes of hospitalization and 
prognosis in patients with cardiovascular diseases. Secular trends in the years 2006-2014 
according to the SILesian CARDiovascular (SILCARD) database. Pol Arch Med Wewn 
2016; 126:754-762. 
6. Lewis EF, Hellkamp AS, Pfeffer MA, Greenspon  AJ, Machado C, Singh S, Schron E,  Lee 
KL, Lamas GA. The association of the heart failure score with mortality and heart failure 
hospitalizations in elderly patients: insights from the Mode Selection Trial  (MOST). Am 
Heart J 2006;151:699-705. 
7. Greene SJ, Mentz RJ, Felker M. Outpatient worsening heart failure as a target for therapy. 
A review. JAMA Cardiology 2018; 3:252-259. 
16 
 
8. Ferreira JP, Metra M, Mordi I, Gregson J, ter Maaten JM, Tromp J, Anker SD, Dickstein K, 
Hillege HL, Ng LL, van Veldhuisen DJ, Lang CC, Voors AA, Zannad F. Heart failure in the 
outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. Eur J Heart Fail 
2019; 21,112-120. 
9. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody 
JM, Gerber TC, Hinderliter AL, King SB III, Klingfield PD, Krumholz HM, Kwong RY, Lim 
MJ, Linderbaum JA, Mack MJ, Munger MA, Prager ML, Sabik JF, Shaw LJ, Sikkema JD, 
Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV. 2012 ACCF/AHA/ACP/AATS/PCNA/ 
SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart 
disease. J Am Coll Cardiol 2012: 60(24):e-44-e164. 
10. Rapsomaniki E, Shah A, Perel P, Denaxa S, George J, Nicholas O, Udumyan R, Feder 
GS, Hingorani AD, Timmis A, Smeeth L, Hemingway H. Prognostic models for stable 
coronary artery disease based on electronic health record cohort of 102 023 patients. Eur 
Heart J 2014; 35:844-852. 
11. Lamblin N, Meurice T, Tricot O, de Groote P, Lemesle G, Bauters C. First hospitalization 
for heart failure in outpatients with stable coronary artery disease: determinants, role of 
incident myocardial infarction, and prognosis. J Card Fail 2018; 24:815-822.   
12. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, 
Swedberg K, Young JB, Michalson EL, Pfeffer MA.  Influence of nonfatal hospitalization for 
heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 
116:1482-1487. 
13. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JMO, Warnica W, Flaker GC, 
Braunwald E, Pfeffer MA. Predictors of late development of heart failure in stable survivirs of 
myocardial infarction. The CARE study. J Am Coll Cardiol 2003;42:1446-1453. 
17 
 
14. Lewis EF, Solomon SD, Jablonski KA, Rice MM, Clemenza F, Hsia J, Maggioni AP, 
Zabalgoita M, Huynh T, Cuddy TE, Gersh BJ, Rouleau J, Braunwald E, Pfeffer MA. 
Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. Circ 
Heart Fail 2009;2:209-216. 
15. Tendera M. Clinical profile of contemporary patients with stable coronary artery disease. 
Medicographia 2017; 39(5):5-10. 
16. Steg PG. Heart rate management in coronary artery disease: the CLARIFY registry. Eur 
Heart J Suppl 2009; 11:D13-D18. 
17. Sorbets E, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Steg PG, on 
behalf of the CLARIFY Investigators. Rationale, design, and baseline characteristics of the 
CLARIFY registry of outpatients with stable coronary artery disease. Clin Cardiol 2017; 
40:797-806. 
18. Bauters C, Tricot O, Meurice T, Lamblin N. Long-term risk and predictors of 
cardiovascular death in stable coronary artery disease. Coron Artery Dis 2017;28:636-641. 
19. Winkel P, Jakobsen JC, Hilden J, Jensen G, Kjoller E, Sajadieh A, Kastrup J, Kolmos HJ, 
Larsson A, Arnlov J, Gluud C. Prognostic value of routinely available data in patients with 
stable coronary heart disease. A 10-year follow-up of patients sampled at random times 
during their disease course. Open Heart 2018; 5:e000808. 
20. Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tendera M, Tavazzi L, Bhatt DL, 
Steg PG. Cardiovascular event rates and mortality according to achieved systolic blood 
pressure in patients with stable coronary artery disease: an international cohort study. Lancet 
2016; 388:2142-2152. 
21. Sorbets E, Fox KM, Elbez Y, Danchin N, Dorian P, Ferrari R, Ford I, Greenlaw N, Kaira 
PR, Parma Z, Shalnova S, Tardif JC, Tendera M, Zamorano JL, Vidal-Petiot E, Steg PG. 
18 
 
Long-term outcomes of chronic coronary syndrome worldwide: insights from the 
international CLARIFY registry. Eur Heart J 2020; 41:347-355. 
22. Steg PG, Greenlaw N, Tendera M, Tardif JC, Ferrari R, Al-Zaibag M, Dorian P, Hu D, 
Shalnova S, Sokin FJ, Ford I, Fox KM, for the CLARIFY Investigators. Prevalence of angina 
symptoms and myocardial ischemia and their effect on  clinical outcomes in outpatients with 
stable coronary artery disease. Data from the international observational CLARIFY registry. 
JAMA Intern Med 2014; 174:1651-1659. 
23. Eisen A, Bhatt DL, Steg PG, Eagle KA, Goto S, Guo J, Smith SC, Ohman EM, Scirica 
BM, on behalf of the REACH registry investigators. Angina and future cardiovascular events 
in stable patients with coronary artery disease: Insights from the Reduction of 
Atherothrombosis for Continued Health (REACH) registry.. J Am Heart Assoc 2016; 
5:e004080 
24. Khan SU, Singh M, Lone AN, Khan MS, Fatima U, Saad AB, Riaz H, Opoku-Asare I, 
Kaluski E. Meta-analysis of long-term outcomes of percutaneous coronary intervention versus 
medical therapy in stable coronary artery disease. Eur J Prev Cardiol 2019; 26;429-432.  
25. Elbez Y, Cheong AP, Fassa AA, Cohen E, Reid CM, Babarskiene R, Bhatt DL, Steg PG. 
Clinical outcomes in patients with stable coronary artery disease with vs. without a history of 
myocardial revascularization. Eur Heart J Qual Care Clin Outcomes 2016; 2:23-32. 
26. Bauters C, Deneve M, Tricot O, Meurice T, Lamblin N. Prognosis of patients with  stable 
coronary artery disease (from the CORONOR study). Am J Cardiol 2014; 113:1142-1145.  
27. Trullas JC, Miro O, Formiga F, Martin-Sanches FJ, Montero-Perez-Barquero M, Jacob J, 
Quiros-Lopea R, Herrero Puente P, Manzano L, Llorens P, and members of the RICA and 
EAHFE registries. The utility of heart failure registries: a descriptive and comparative study 





Figure 1. Patient flow 
Figure 2. Kaplan-Meier curves for the primary and secondary outcome  
Figure 3. Multivariable predictors of the primary outcome (CV death, hospitalization for heart 
failure  or new heart failure symptoms) 
Figure 4. Multivariable predictors of the secondary outcome (CV death or hospitalization for 
heart failure) 
Supplementary Figure 1. Multivariable predictors of the combined outcome including new 





















Table 1. Patient characteristics at baseline 
Parameter 
(number of patients with 
data available) 
Total 
N = 26769 
Primary 
outcome 
N = 4393 
No primary 
outcome 







 Demographic characteristics 
Age, years (N = 26 763); mean 
(SD) 

















Ethnicity (N = 26769); N (%) 
  Caucasian 
  Asian 
  Hispanic 
  Black/African 





















Cardiovascular risk factors; 
N (%) 
Dyslipidaemia (N = 26767) 
Hypertension (N = 26767) 





















Medical history; N (%) 













(N = 26769) 
   CABG or PCI 
   Both CABG and PCI  
   PCI only 
   CABG only 
PAD (N = 26767) 
Carotid disease (N = 26769) 
Stroke (N = 26768) 
Asthma/COPD (N = 26769) 
Symptomatic status (N = 
26768) 

























































Cardiac parameters; N (%) 
Heart rate, bpm (N + 26747) 
  <60 
  60-80 
  >80 
Systolic BP, mmHg (N = 
26749) 
  <120 
  120-140 
  >140 
















































  <70 
  70-90 
  >90 
Heart rhythm (ECG) (N = 
26769) 
  Sinus 
  Atrial fibrillation 
  Paced 
  Not available 
LV ejection fraction; % (N = 
26769) 
  >50 
  40-50 
  <40 
  Not available 
Number of arteries with >50% 
stenosis on angiography (N = 
26741) 
  0 
  1 
  2-3 



























































































Abbreviations: BP – blood pressure; bpm – beats per minute; CABG – coronary artery bypass 
grafting; CCS – Canadian Cardiovascular Society; COPD – chronic obstructive pulmonary 
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disease; LV – left ventricle; PAD – peripheral artery disease; PCI – percutaneous coronary 
intervention. 
 










All subjects  







per 1000 PY 
 
CV death, hospitalization for HF, or new HF 
symptoms 
CV death or hospitalization for HF 
Hospitalization for HF or new HF symptoms 
All-cause death 
CV death 
Hospitalization for HF 




















CV – cardiovascular; HF – heart failure; PY – patient-years; ^ - patients in whom new HF 
symptoms and hospitalization for HF were reported on the same day are reported as HF 
hospitalization only. 
 




